

Vanda Pharmaceuticals Inc.
Form 4
June 04, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Clark William D

(Last) (First) (Middle)
9605 MEDICAL CENTER
DRIVE, SUITE 300

(Street)

ROCKVILLE, MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vanda Pharmaceuticals Inc. [VNDA]

3. Date of Earliest Transaction
(Month/Day/Year)
06/01/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
Sr. VP, Chief Business Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2007 ⁽¹⁾		M		3,200	A	\$ 0.331
Common Stock	06/01/2007 ⁽¹⁾		S		194	D	\$ 20.01
Common Stock	06/01/2007 ⁽¹⁾		S		100	D	\$ 20.02
Common Stock	06/01/2007 ⁽¹⁾		S		200	D	\$ 20.05
Common Stock	06/01/2007 ⁽¹⁾		S		200	D	\$ 20.05

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

Common Stock	06/01/2007 ⁽¹⁾	S	500	D	\$ 20.07	2,006	D
Common Stock	06/01/2007 ⁽¹⁾	S	200	D	\$ 20.1	1,806	D
Common Stock	06/01/2007 ⁽¹⁾	S	100	D	\$ 20.11	1,706	D
Common Stock	06/01/2007 ⁽¹⁾	S	1,120	D	\$ 20.12	586	D
Common Stock	06/01/2007 ⁽¹⁾	S	100	D	\$ 20.17	486	D
Common Stock	06/01/2007 ⁽¹⁾	S	100	D	\$ 20.19	386	D
Common Stock	06/01/2007 ⁽¹⁾	S	100	D	\$ 20.21	286	D
Common Stock	06/01/2007 ⁽¹⁾	S	12	D	\$ 20.22	274	D
Common Stock	06/01/2007 ⁽¹⁾	S	174	D	\$ 20.23	100	D
Common Stock	06/01/2007 ⁽¹⁾	S	100	D	\$ 20.24	0	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Employee Stock Option	\$ 0.331	06/01/2007 ⁽¹⁾		M	3,200	⁽²⁾ 02/10/2015	Common Stock	3,200

(Right to
Buy)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Clark William D 9605 MEDICAL CENTER DRIVE SUITE 300 ROCKVILLE, MD 20850			Sr. VP, Chief Business Officer	

Signatures

/s/William D.
Clark

06/04/2007

__Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction was administered pursuant to an authorized 10b5-1 plan.
- (2) Exercisable with respect to 25% of the shares one year after the grant, exercisable with respect to an additional 2.08333% of the aggregate shares each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.